Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARLSMED, INC.CARL · Entity 5551 | Director | June 03, 2026 | June 22, 2026 |
| GenMark Diagnostics, Inc.GNMK · Entity 140086 | Director | April 22, 2021 | April 22, 2021 |
| Outset Medical, Inc.OM · Entity 7026 | Director | June 04, 2026 | June 05, 2026 |
| Sientra, Inc.SIEN · Entity 108294 | Director | June 09, 2022 | June 14, 2022 |
| iRhythm Holdings, Inc.IRTC · Entity 1499 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARLSMED, INC.
Report date June 03, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,031 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 13,698 · Balance 31,031 F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
GenMark Diagnostics, Inc.
Report date April 22, 2021 · Filed April 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 1
1 source rowRow 1 · 2021-04-22 · Other · Disposed 131,678 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F2: Includes 28,128 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2022-01-03 | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-22 · Disposition to issuer · Disposed 13,426 · Balance 0 F3: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Includes 28,128 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU.
F3: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof.
Outset Medical, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,785 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,667 · Balance 34,785 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders
Sientra, Inc.
Report date June 09, 2022 · Filed June 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,978 |
Reported balance
After 2022-06-09 transaction · row 1
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 103,306 · Balance 220,978 F1: The Restricted Stock Units shall vest on the earlier to occur of: (i) the day prior to the 2023 Annual Shareholders Meeting or (ii) on the one (1) year anniversary of the Annual Shareholders Meeting on which the Restricted Stock Award was granted, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units shall vest on the earlier to occur of: (i) the day prior to the 2023 Annual Shareholders Meeting or (ii) on the one (1) year anniversary of the Annual Shareholders Meeting on which the Restricted Stock Award was granted, subject to continued service.
iRhythm Holdings, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,608 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 1,573 · Balance 3,608 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 43,396 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Wright Medical Group N.V.
Report date November 11, 2020 · Filed November 13, 2020
Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 1
1 source rowRow 1 · 2020-11-11 · Other · Disposed 16,306 · Balance 0 F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 26,063 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-11 · Disposition to issuer · Disposed 11,691 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-11 · Disposition to issuer · Disposed 9,907 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-11 · Disposition to issuer · Disposed 10,275 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-11 · Disposition to issuer · Disposed 11,765 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-11 · Disposition to issuer · Disposed 11,018 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2024-08-12 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-11 · Disposition to issuer · Disposed 6,034 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.45 · Expires 2023-08-09 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-11 · Disposition to issuer · Disposed 7,538 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.04 · Expires 2022-08-10 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-11 · Disposition to issuer · Disposed 6,448 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.20 · Expires 2021-05-12 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-11 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 26,063 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Other · Disposed 11,985 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, out of the total of 11,985 shares held by the Reporting Person, (i) 10,952 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,033 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2022-06-14 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-28 · Other · Disposed 1,391 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.21 · Expires 2021-07-28 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-28 · Other · Disposed 40,871 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.34 · Expires 2023-06-18 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-04-28 · Other · Disposed 10,645 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2024-05-29 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-28 · Other · Disposed 30,000 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, out of the total of 11,985 shares held by the Reporting Person, (i) 10,952 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,033 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.
F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 5, 2019 16:34 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 6,417 | $32.00 | $205,344.00 |
DisclosureSEC source: 0001235802-19-000021 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,390 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 16:17 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 3,583 | $32.01 | $114,679.65 |
DisclosureSEC source: 0001235802-19-000014 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,807 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.03, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 16:19 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionStock Option (right to buy) · Derivative | 30,816 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001235802-19-000010 · primary_doc.xml · derivative · entry 6 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,816 shares Expires 2020-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · derivative.exercise_date: This option has fully vested. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 16:19 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 30,816 | $30.07 | $926,566.24 |
DisclosureSEC source: 0001235802-19-000010 · primary_doc.xml · nonDerivative · entry 4 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,390 F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.19, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 16:19 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionOrdinary Shares, par value EUR 0.03 per share | 30,816 | $22.50 | $693,360.00 |
DisclosureSEC source: 0001235802-19-000010 · primary_doc.xml · nonDerivative · entry 3 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 16:19 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionStock Option (right to buy) · Derivative | 1,907 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001235802-19-000010 · primary_doc.xml · derivative · entry 5 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,816 Underlying: Ordinary Shares · 1,907 shares Expires 2020-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · derivative.exercise_date: This option has fully vested. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 16:19 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 1,907 | $30.00 | $57,210.00 |
DisclosureSEC source: 0001235802-19-000010 · primary_doc.xml · nonDerivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,390 F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.10, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 16:19 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionOrdinary Shares, par value EUR 0.03 per share | 1,907 | $22.50 | $42,907.50 |
DisclosureSEC source: 0001235802-19-000010 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 16:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionStock Option (right to buy) · Derivative | 4,537 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001235802-18-000163 · primary_doc.xml · derivative · entry 6 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,723 Underlying: Ordinary Shares · 4,537 shares Expires 2020-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option has fully vested. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 16:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 4,537 | $30.02 | $136,206.64 |
DisclosureSEC source: 0001235802-18-000163 · primary_doc.xml · nonDerivative · entry 4 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,390 F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.10, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 16:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionOrdinary Shares, par value EUR 0.03 per share | 4,537 | $22.50 | $102,082.50 |
DisclosureSEC source: 0001235802-18-000163 · primary_doc.xml · nonDerivative · entry 3 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 16:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionStock Option (right to buy) · Derivative | 12,740 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001235802-18-000163 · primary_doc.xml · derivative · entry 5 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,260 Underlying: Ordinary Shares · 12,740 shares Expires 2020-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: This option has fully vested. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 16:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 12,740 | $30.14 | $384,030.74 |
DisclosureSEC source: 0001235802-18-000163 · primary_doc.xml · nonDerivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,390 F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.35, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 16:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Exercise / conversionOrdinary Shares, par value EUR 0.03 per share | 12,740 | $22.50 | $286,650.00 |
DisclosureSEC source: 0001235802-18-000163 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were exercised and sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F3 · balance_after: Total holdings were increased by one ordinary share due to a rounding error in the Form 4 report that was filed with the SEC on July 26, 2018. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 20:43 UTC | Wright Medical Group N.V. wMGI · Entity 145358 | Tax withholdingOrdinary Shares, par value EUR 0.03 per share | 626 | $24.83 | $15,543.58 |
DisclosureSEC source: 0001235802-18-000113 · primary_doc.xml · nonDerivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,389 F3 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 20:43 UTC | Wright Medical Group N.V. wMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 9,907 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0001235802-18-000113 · primary_doc.xml · derivative · entry 3 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,907 Underlying: Ordinary Shares · 9,907 shares Expires 2028-07-24 F4 · derivative.exercise_date: This option vests in two annual installments, on the one-year and two-year anniversaries of July 24, 2018. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 20:43 UTC | Wright Medical Group N.V. wMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 3,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-18-000113 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,015 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Includes 7,390 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 00:25 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock (RSUs) | 6,116 | $20.44 | $125,011.04 |
DisclosureSEC source: 0001209191-18-036532 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,069 F1 · shares: The Common Stock underlying this grant of restricted stock will vest on the earlier to occur of: (i) the day prior to the annual meeting of stockholders for the year following the date of grant or (ii) the one (1) year anniversary of the annual meeting of stockholders of the year of grant, subject to continued service as a director of the Issuer. Read SEC document |
| May 24, 2018 Filed May 29, 2018 19:02 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 18,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-18-000128 · wf-form4_152763492790366.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,461 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:05 UTC | Sientra, Inc. SIEN · Entity 108294 | PurchaseCommon Stock | 7,407 | $13.50 | $99,994.50 |
DisclosureSEC source: 0001209191-18-028904 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,953 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 17:06 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 10,275 | $0.00 Strike: $27.86 | $0.00 |
DisclosureSEC source: 0001235802-17-000121 · primary_doc.xml · derivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,275 Underlying: Ordinary Shares · 10,275 shares Expires 2027-07-25 F3 · derivative.exercise_date: This option vests in two annual installments, on the one-year and two-year anniversaries of July 25, 2017. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 17:06 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 3,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-17-000121 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,211 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Includes 3,586 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 16:19 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Tax withholdingOrdinary Shares, par value EUR 0.03 per share | 1,428 | $27.58 | $39,384.24 |
DisclosureSEC source: 0001235802-17-000109 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 23:36 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock | 12,861 | $9.72 | $125,008.92 |
DisclosureSEC source: 0000899243-17-017261 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,546 F1 · shares: The common stock underlying this grant of restricted stock will vest on the earlier to occur of: (i) day prior to the annual meeting of stockholders for the year following the date of grant, or (ii) the one-year anniversary of the annual meeting of stockholders of the year of grant, subject to continued service as a director. Read SEC document |
| May 25, 2017 Filed May 30, 2017 18:42 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 7,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000126 · wf-form4_149618411381160.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,595 F1 · shares: The amount reported reflects restricted stock units granted to the reporting person pursuant to the Issuer's 2010 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:55 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | OtherStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001209191-17-028626 · doc4.xml · derivative · entry 5 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2024-05-29 F3 · derivative.exercise_date: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:55 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | OtherStock Options (Right to Buy) · Derivative | 10,645 | $0.00 Strike: $6.34 | $0.00 |
DisclosureSEC source: 0001209191-17-028626 · doc4.xml · derivative · entry 4 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,645 shares Expires 2023-06-18 F3 · derivative.exercise_date: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:55 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | OtherStock Options (Right to Buy) · Derivative | 40,871 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001209191-17-028626 · doc4.xml · derivative · entry 3 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,871 shares Expires 2021-07-28 F3 · derivative.exercise_date: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:55 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | OtherStock Options (Right to Buy) · Derivative | 1,391 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-17-028626 · doc4.xml · derivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,391 shares Expires 2022-06-14 F3 · derivative.exercise_date: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:55 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | OtherCommon Stock | 11,985 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-028626 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2 · kind: Pursuant to the terms of the Merger Agreement, out of the total of 11,985 shares held by the Reporting Person, (i) 10,952 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,033 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, out of the total of 11,985 shares held by the Reporting Person, (i) 10,952 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,033 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. Read SEC document |
| October 13, 2016 Filed Oct 17, 2016 16:22 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Tax withholdingOrdinary Shares, par value EUR 0.03 per share | 1,177 | $23.71 | $27,906.67 |
DisclosureSEC source: 0001235802-16-000318 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,053 F1 · balance_after: Includes 4,094 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 11:26 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.34 | $0.00 |
DisclosureSEC source: 0001209191-16-141910 · doc4.xml · derivative · entry 3 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,645 Underlying: Common Stock · 7,500 shares Expires 2023-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 11:26 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | SaleCommon Stock | 7,500 | $40.08 | $300,612.00 |
DisclosureSEC source: 0001209191-16-141910 · doc4.xml · nonDerivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,985 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.245, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 11:26 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Exercise / conversionCommon Stock | 7,500 | $6.34 | $47,550.00 |
DisclosureSEC source: 0001209191-16-141910 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.